Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

ECOR vs ACEP: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ECOR Wins Head-to-Head Institutional Verdict (4–0 across 6 Pillars · 6–2 Matrix Metrics)

ECOR Overall Winner 6-Pillar Tally: ECOR 4 – 0 ACEP (2 Tie) Matrix Metrics: ECOR 6 – 2 ACEP

As of Nov 19, 2026, electroCore, Inc. (ECOR) is the stronger overall head-to-head candidate over ACEP (ACEP) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ECOR carries a Unified Composite Score of 56.8/100 (HOLD) at $4.85 (N/M Forward P/E, -33.1% operating margin), whereas ACEP carries 52.6/100 (HOLD) at $18.92 (N/M Forward P/E, N/A operating margin).

  • Technical & Structure Timing Caution: ECOR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.5); meanwhile ACEP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ECOR vs ACEP
ECOR NASDAQ Head-to-Head Winner
electroCore, Inc. Common Stock
Electromedical & Electrotherapeutic Apparatus
$4.85
-6.19% 1D
Market Cap $47.7M
TTM Revenue $38M
Forward P/E N/M
Beta / 30D Vol 1.52β · 155% Vol
Unified Composite Score
56.8 / 100 HOLD
Tech 68.0 Fund 53.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -11.5%), weak momentum, RSI 32
RSI-14: 31.5 · SMA20: $6.90 · SMA50: $8.67
ACEP US Equity
ACEP
Institutional Equity
$18.92
-1.45% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.84β · 20% Vol
Unified Composite Score
52.6 / 100 HOLD
Tech 51.0 Fund 51.0 Flow 50.0 Mom 70.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -1.8%), weak momentum, RSI 32
RSI-14: 31.6 · SMA20: $19.85 · SMA50: $19.96

6-Pillar Scorecard Institutional Category Breakdown (ECOR 4 – 0 ACEP)

Columns: Metric · ECOR · ACEP
1. Valuation Multiples ECOR
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 1.4x N/M
2. Growth & Scale ECOR
Revenue Growth (YoY) +11.5% N/A
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) $38M N/A
Market Cap $47.7M N/A
3. Profitability & Quality ECOR
Gross Margin 87.7% N/A
Operating Margin -33.1% N/A
Net Profit Margin -33.5% N/A
Return on Equity (ROE) -478.7% N/A
4. Balance Sheet & Cash Flow ECOR
Cash Generation (TTM) -$6.9M N/A
Cash Flow Margin -18.1% N/A
Net Cash / Leverage $4.6M Net Debt N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ECOR (6) vs ACEP (2)
Institutional Metric ECOR ACEP Criterion Row Edge
Market Capitalization
Scale
$47.7M N/A Larger Scale ECOR
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+11.5% N/A Higher Growth ECOR
Operating Margin (TTM)
Profitability
-33.1% N/A Higher Margin ECOR
Net Profit Margin
Profitability
-33.5% N/A Higher Margin ECOR
Return on Equity (ROE)
Capital Efficiency
-478.7% N/A Higher ROE ECOR
52-Week Range Position
Momentum
6% ($4–$13) 65% ($15–$21) Stronger Trend ACEP
Beta / 30D Volatility
Risk Regime
1.52β · 155% Vol 0.84β · 20% Vol Lower Realized Risk ACEP
Unified Institutional Score
Composite Signal
56.8 / 100 (HOLD) 52.6 / 100 (HOLD) Higher Composite ECOR
Trailing 12M Revenue (USD)
Operating Scale
$38M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
87.7% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.4x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$6.9M ($4.6M Net Debt) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ACEP +28.2 pp
ECOR: -34.01% · ACEP: -5.81%
3M Horizon ACEP +44.16 pp
ECOR: -53.9% · ACEP: -9.74%
6M Horizon ACEP +16.4 pp
ECOR: -19.03% · ACEP: -2.63%
1Y Horizon ACEP +22.13 pp
ECOR: +2.97% · ACEP: +25.1%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ECOR vs ACEP. Trailing 12-month operating profitability (ECOR -33.1% vs ACEP N/A) and valuation multiples (ECOR N/M vs ACEP N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ECOR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$38M
Gross Margin87.7%
Op. Margin-33.1%
ROE / Fwd P/E-478.7% · N/M
ACEP ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ECOR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ECOR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ACEP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ACEP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ECOR Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $47.7M market capitalization and -33.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ACEP Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ECOR vs ACEP Key Questions & Quantitative Answers

As of Nov 19, 2026, electroCore, Inc. (ECOR) is the stronger overall head-to-head candidate over ACEP (ACEP) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ECOR carries a Unified Composite Score of 56.8/100 (HOLD) at $4.85 (N/M Forward P/E, -33.1% operating margin), whereas ACEP carries 52.6/100 (HOLD) at $18.92 (N/M Forward P/E, N/A operating margin). Technical & Structure Timing Caution: ECOR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.5); meanwhile ACEP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ECOR leads the Growth & Scale pillar: ECOR posts +11.5% YoY revenue growth and +0.0% YoY earnings growth on $38M TTM revenue (87.7% gross margin, -33.1% operating margin), compared with ACEP at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, ECOR generates $38M in USD-normalized revenue versus N/A for ACEP. In operating R&D and SG&A reinvestment, ECOR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ACEP.

ECOR screens cheaper on headline valuation multiples. ECOR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.4x EV/Revenue (-18.1% FCF margin), whereas ACEP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ECOR (-478.7% ROE) versus ACEP (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, ECOR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.52β · 155% Vol realized risk). By comparison, ACEP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.84β · 20% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.